卡麦角林治疗高催乳素血症患者心脏瓣膜异常患病率的随访研究
英国13个内分泌中心对既往队列中192例持续使用多巴胺激动剂至少2年的高催乳素血症患者进行随访超声心动图检查,首次与第二次检查时卡麦角林累积剂量中位数分别为97 mg与232 mg;未观察到多巴胺激动剂累积剂量与年龄校正后任何瓣膜异常患病率之间存在关联。
要点
- 192例患者中,两次超声心动图之间持续卡麦角林治疗的中位时间为34个月。
- 首次与第二次超声心动图时的卡麦角林累积剂量中位数分别为97 mg和232 mg。
- 未观察到多巴胺激动剂累积剂量与年龄校正后任何瓣膜异常患病率之间的关联。
核心结论
- 这项英国大型随访研究不支持多巴胺激动剂用于治疗高催乳素血症与心脏瓣膜病之间存在有临床意义的关联。
研究设计与样本
- 随访超声心动图研究,纳入既往报告队列中的部分患者,来自英国13个二级/三级内分泌诊疗中心,共192例(男81例;中位年龄51岁,四分位距42-62)。
- 全部患者在观察期间均持续接受多巴胺激动剂治疗至少2年;超声心动图检查按英国超声心动图学会成人经胸超声心动图最低标准执行。
- 采用广义估计方程并结合后退法,以卡麦角林累积剂量最低三分位组为参照,计算瓣膜心脏异常的比值比。
主要发现
- 首次与第二次超声心动图时的卡麦角林累积剂量中位数(四分位距)分别为97 mg(20-377)和232 mg(91-551)。
- 两次超声心动图之间持续卡麦角林治疗的中位时间(四分位距)为34个月(24-42)。
- 未观察到所用药物的多巴胺激动剂累积剂量与年龄校正后任何瓣膜异常患病率之间存在关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate. OBJECTIVE: Our objective was to provide follow-up echocardiographic data on a previously described cohort of patients treated with DA for lactotrope pituitary tumors and to explore possible associations between structural and functional valve abnormalities with the cumulative dose of drug used. DESIGN: Follow-up echocardiographic data were collected from a proportion of our previously reported cohort of patients; all had received continuous DA therapy for at least 2 years in the intervening period. Studies were performed according to British Society of Echocardiography minimum standards for adult transthoracic echocardiography. Generalized estimating equations with backward selection were used to determine odds ratios of valvular heart abnormalities according to tertiles of cumulative cabergoline dose, using the lowest tertile as the reference group. SETTING: Thirteen centers of secondary/tertiary endocrine care across the United Kingdom were included. RESULTS: There were 192 patients (81 males; median age, 51 years; interquartile range [IQR], 42-62). Median (IQR) cumulative cabergoline doses at the first and second echocardiograms were 97 mg (20-377) and 232 mg (91-551), respectively. Median (IQR) duration of uninterrupted cabergoline therapy between echocardiograms was 34 months (24-42). No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality. CONCLUSION: This large UK follow-up study does not support a clinically significant association between the use of DA for the treatment of hyperprolactinemia and cardiac valvulopathy.
引用
- Drake WM, Stiles CE, Bevan JS, et al. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. J Clin Endocrinol Metab. 2016. PMID: 27571182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。